Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
February 18 2021 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
company focused on developing and commercializing new chemical
entities designed to alleviate pruritus by selectively targeting
peripheral kappa opioid receptors, today announced that the Company
will host a conference call and live audio webcast on Thursday,
February 25, 2021, at 4:30 p.m. ET to report fourth quarter and
full year 2020 financial results and provide a corporate update.
To participate in the conference call, please
dial (855) 445-2816 (domestic) or (484) 756-4300 (international)
and refer to conference ID 6676157. A live webcast of the call can
be accessed under “Events & Presentations” in the News &
Investors section of the Company’s website at
www.CaraTherapeutics.com.
An archived webcast recording will be available
on the Cara website beginning approximately two hours after the
call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors, or KORs. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body’s peripheral nervous system, as well as
certain immune cells. The Company has submitted a New Drug
Application (NDA) to the U.S. Food and Drug
Administration (FDA) for KORSUVA™ Injection (difelikefalin)
for the treatment of moderate-to-severe pruritus in hemodialysis
patients. KORSUVA Injection received Breakthrough Therapy
Designation from the FDA for this indication. Cara has requested
Priority Review for the NDA which, if granted, could result in a
six-month review process. Oral KORSUVA has successfully completed a
Phase 2 trial for the treatment of pruritus in patients with CKD
and is currently in Phase 2 trials in atopic dermatitis and primary
biliary cholangitis patients with moderate-to-severe pruritus.
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
MEDIA CONTACT:Claire LaCagnina6
Degrees315-765-1462clacagnina@6degreespr.com
INVESTOR CONTACT:Janhavi MohiteStern Investor
Relations, Inc.212-362-1200 janhavi.mohite@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024